Format

Send to

Choose Destination
J Control Release. 2018 Feb 10;271:1-20. doi: 10.1016/j.jconrel.2017.12.019. Epub 2017 Dec 19.

Organogels, promising drug delivery systems: an update of state-of-the-art and recent applications.

Author information

1
Laboratoire de Nanotechnologies Pharmaceutiques, faculté de pharmacie, Université de Montréal, CP6128, succursale Centre-ville, Montréal, QC, H3C 3J7, Canada.
2
Université de Lyon (UCBL), Biologie Tissulaire et Ingénierie Thérapeutique UMR 5305 et Vecteurs Colloïdaux et Transport Tissulaire, Institut des Sciences Pharmaceutiques et Biologiques, 8 avenue Rockefeller, 69373 Lyon, Cedex 08, France. Electronic address: plamen.kirilov@univ-lyon1.fr.
3
Laboratoire de Nanotechnologies Pharmaceutiques, faculté de pharmacie, Université de Montréal, CP6128, succursale Centre-ville, Montréal, QC, H3C 3J7, Canada. Electronic address: vg.roullin@umontreal.ca.

Abstract

Organogels are semi-solid systems with an organic liquid phase immobilized by a three-dimensional network composed of self-assembled, crosslinked or entangled gelator fibers. Organogel applications are various, including chemistry, pharmaceuticals, cosmetics, biotechnologies and food technology. In pharmacology, they are used as drug and vaccine delivery platforms for active ingredients via diverse routes such as transdermal, oral and parenteral. In a close past, their uses as drug delivery systems have been unfortunately hampered by the toxicity of the selected organic solvents. More recently, the synthesis of more biocompatible organogels has strengthened the development of several biomedical and pharmaceutical applications. This review provides a global view of organogels, such as nature, syntheses, characterizations and properties. An emphasis is placed on the most recent technologies used in the design of organogels as potential controlled delivery systems. A particular attention is provided to their newest therapeutic applications.

KEYWORDS:

Bigel; Characterization; Drug delivery; Organogel; Organogelator; Semi-solid dosage form

PMID:
29269143
DOI:
10.1016/j.jconrel.2017.12.019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center